Tirzepatide benefits people with obesity, kidney disease and heart failure Drug improves outcomes among high-risk patient population with significant unmet need Peer-Reviewed Publication ...

Assessing individual endpoints, worsening HF events occurred in 8% of tirzepatide participants and in 14.2% of placebo participants, for an HR of 0.54 (95% CI, 0.34-0.85), whereas adjudicated CV ...

Benefits include significant weight loss, improved insulin sensitivity, convenient oral format, enhanced metabolic health, and a favorable safety profile. How do I take GetSimpli Oral Tirzepatide?

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

GLP-1 receptor agonists like semaglutide have demonstrated benefits in slowing the progression of kidney disease in patients with diabetes. Tirzepatide may have similar advantages.

As prices come down and new benefits emerge, universal access to GLP-1s could become sound fiscal policy. Gary Winslett is an ...

A post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials found that early responders to tirzepatide, or those who lost at least 5% of body weight by 8 weeks, had greater weight loss and ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, Eli Lilly announced the topline results from its SURPASS-CVOT ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

These findings support the idea that tirzepatide has lasting benefits even after discontinuation. This is the first real-world evidence of post-treatment weight loss durability with tirzepatide in ...